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XYLT1 Mutations in Desbuquois Dysplasia Type 2
Catherine Bui,1,8 Ce´line Huber,1,8 Beyhan Tuysuz,2 Yasemin Alanay,3 Christine Bole-Feysot,4
Jules G. Leroy,5 Geert Mortier,6 Patrick Nitschke,7 Arnold Munnich,1 and Vale´rie Cormier-Daire1,*
Desbuquois dysplasia (DBQD) is a severe condition characterized by short stature, joint laxity, and advanced carpal ossification. Based on
the presence of additional hand anomalies, we have previously distinguished DBQD type 1 and identified CANT1 (calcium activated
nucleotidase 1) mutations as responsible for DBQD type 1. We report here the identification of five distinct homozygous xylosyltrans-
ferase 1 (XYLT1) mutations in seven DBQD type 2 subjects from six consanguineous families. Among the five mutations, four were ex-
pected to result in loss of function and a drastic reduction of XYLT1 cDNA level was demonstrated in two cultured individual fibroblasts.
Because xylosyltransferase 1 (XT-I) catalyzes the very first step in proteoglycan (PG) biosynthesis, we further demonstrated in the two
individual fibroblasts a significant reduction of cellular PG content. Our findings of XYLT1 mutations in DBQD type 2 further support
a common physiological basis involving PG synthesis in the multiple dislocation group of disorders. This observation sheds light on the
key role of the XT-I during the ossification process.Introduction
Desbuquois dysplasia (DBQD [MIM 251450]) belongs to
the multiple dislocation group of disorders (group 20,
international classification of skeletal disorders).1 It is char-
acterized by dislocations of large joints, severe pre- and
postnatal growth retardation (5 SD), joint laxity, and
flat face with prominent eyes. Radiological features include
short long bones with a monkey wrench appearance of the
proximal femora (exaggerated trochanter) and advanced
carpal and tarsal ossification. Based on the presence or
absence of additional hand anomalies (ranging from extra
ossification center distal to the second metacarpal, delta
phalanx, or bifid distal phalanx of the thumb), we have
distinguished DBQD type 1 from DBQD type 2.2,3
In 2009, we identified CANT1 (calcium activated nucleo-
tidase 1 [MIM 613165]) mutations as responsible for DBQD
type 1.4 CANT1mutations have then been reported in the
‘‘Kim variant’’ of DBQD, characterized by shortmetacarpals
and elongated middle and proximal phalanges but very
short distal phalanges.5,6 All subjects with the Kim variant
were of Japanese or Korean origin and had a p.Val226Met
substitution on at least one allele, with a shared common
haplotype, supporting a founder effect in this population.
After our initial study, we screened CANT1 in a series
of 38 DBQD-affected individuals and found CANT1 muta-
tions not only in all subjects with DBQD type 1 but also in
a Kim variant subject and in one atypical DBQD-affected
individual with thumb anomaly and major joint disloca-
tions.7 However, none of our 30 DBQD type 2 individuals
was found to carry a CANT1 mutation.7
DBQD types 1 and 2 have overlapping features with
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The Ame150250) resulting from FLNB mutations (MIM 603381),8
the spondylo-epiphyseal dyplasia form with dislocations
(MIM 143095) resulting from chondroitin 6-O-sulfotrans-
ferase 3 (C6ST-1) (CHST3 [MIM 603799]) mutations,9 the
diastrophic dysplasia (DTD [MIM 222600]) resulting from
solute carrier family 26 (sulfate transporter) member 2
(SLC26A2 [MIM 606718]) mutations,10 and a chondro-
dysplasia with joint dislocations resulting from IMPAD1
(inositol monophosphatase domain-containing protein 1
[MIM 614010]) mutations.11 Apart from Larsen syndrome,
all these disorders are characterized by a reduced amount
of proteoglycans (PGs), which are known to be essential
macromolecules with a large panel of functions, including
extracellular matrix organizers and cell signaling media-
tors.12 PGs are composed of a core protein with at least
one glycosaminoglycan (GAG) chain attached via a Ser-
Gly consensus motif and can be either located at the cell
surface or secreted in the extracellular matrix.12
Because of the clinical overlap of this group of disorders,
we screenedCHST3, SLC26A2, and IMPAD1 in the remaining
DBQD type 2 individuals and found a homozygous CHST3
mutation in 1/3013 and IMPAD1mutations in 2/30 subjects.
Among the remaining 27 DBQD type 2 subjects with no
known molecular basis, only 20 with detailed clinical and
radiological data and regular follow-up were included
in our study. To identify the DBQD type 2 gene, we selected
two siblings from consanguineous parents for whole-
exome sequencing analysis and eventually identified ho-
mozygous mutations in seven individuals from six families
in the xylosyltransferase 1 gene (XYLT1 [MIM 608124]).
XYLT1 encodes xylosyltransferase 1 (XT-I, EC 2.4.2.26),
which is involved in PG synthesis.12 Indeed, the very first
step of this process consists of the initiation of theParis Cite´, Institut Imagine, Hoˆpital Necker Enfants Malades (AP-HP), Paris
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Figure 1. Clinical Features of One DBQD Type 2 Subject with
XYLT1 Mutation
Individual 7 (family 6) at 12 months. Note the flat face, narrow
thorax, short limbs (A) with hip dislocation, hyperlaxity of fingers
(B), and deviation of toes (C).glycosaminoglycan (GAG) chains and can be catalyzed by
the two paralogs XT-I and XT-II.14Material and Methods
Individuals
The 20 DBQD-affected individuals selected for this the study
fulfilled the diagnostic criteria for DBQD type 2, namely severe
pre- and postnatal short stature, short extremities, dislocations
with monkey wrench appearance of the femora, short long bones
with metaphyseal widening, epiphyseal dysplasia, and advanced
carpal and tarsal ossification (Figure 1). Among them, the two
siblings selected for whole-exome sequencing analysis were born
to healthy consanguineous Tunisian parents (f ¼ 1/32). At birth,406 The American Journal of Human Genetics 94, 405–414, March 6they both had a severe short stature, hypotonia, flat face with
prominent eyes, hyperlaxity, hip dislocation, and narrow thorax
leading to a respiratory distress that spontaneously resolved in
the first year of life. Skeleton X-rays showed a monkey wrench
appearance of the femoral neck, epiphyseal dysplasia, knee dislo-
cation, and advanced carpal bone age (Figure 2, Table 1).Samples
Informed consent for participation and sample collection were
obtained via protocols approved by the Necker Hospital ethics
board committee. Venous blood was obtained for DNA extraction
from DBQD-affected individuals (QIAamp DNA blood Maxi kit,
QIAGEN). Fibroblast cultures were established from skin biopsies
obtained from scalp incision.Exome Sequencing
Exome capture was performed at the genomic platform of Foun-
dation IMAGINE (Paris, France) with the SureSelect Human All
Exon kit (Agilent Technologies).15 Single-end sequencing was
performed on an Illumina Genome Analyzer IIx (Illumina) gener-
ating 72-base reads. Sequence data were analyzed by the Bio-
informatic platform and visualized via the interface created by
the Bioinformatic platform (Universite´ Paris Descartes, Paris). For
sequence alignment, variant calling, and annotation, the se-
quences were aligned to the human genome reference sequence
(UCSC Genome Browser, hg18 build) by BWA aligner.16 Down-
stream processing was carried out with the Genome Analysis Tool-
kit (GATK),17 SAMtools18 and Picard Tools. Substitution calls were
made with GATK Unified Genotyper, whereas indel calls were
made with a GATK IndelGenotyperV2. All calls with a read
coverage%23 and a Phred-scaled SNP quality of%20 were filtered
out. All the variants were annotated with an in-house-developed
annotation software system.Microsatellite Analysis of XYLT1 Locus
Microsatellite analysis was performed in consanguineous families
at the XYLT1 locus on chromosome 16p12.3, by means of fourFigure 2. Radiological Features of
Two DBQD Type 2 Subjects with XYLT1
Mutations
(A) Subject 1 (family 1) at 8 months. Note
the monkey wrench appearance of the
proximal femora, absence of upper femoral
epiphyseal centers (a), knee dislocation (b),
short long bones (c), and advanced carpal
bone age (d).
(B) Subject 4 (family 3) at 12 years of age.
Note the scoliosis with irregular vertebral
endplates (a), monkey wrench appearance
of the proximal femora with short femoral
necks, short and broad iliac wings (b), flat
knee epiphyses (c), short metacarpals, and
advanced carpal bone age and prominent
wrist epiphyses (d).
, 2014
Table 1. Clinical Features of the Seven DBQD Type 2-Affected Individuals from Six Families
Ethnic
Origin Csg Parameters at Birth
Clinical Features
at First Exama Radiological Features Follow-up: Growth and Skeleton Other
Family 1,
sibling 1
(female)
Tunisian 1/32 length 37 cm (term) hyperlaxity
respiratory distress
hypotonia
flat face
monkey wrench of the
femoral neck
epiphyseal dysplasia
knee dislocation
advanced carpal bone age
at 24 years of age: height 111.5 cm (< 6 SD) mild intellectual disability
Family 1,
sibling 2
(male)
Tunisian 1/32 length 41 cm (term) hypotonia
narrow thorax
hip dislocation
flat face
monkey wrench of the
femoral neck
epiphyseal dysplasia
knee dislocation
advanced carpal bone age
at 20 years of age: height 121 cm (< 6 SD) intellectual disability
Family 2
(female)
Mauritian 1st cousins weight 2,000 g lower limb deformity
multiple dislocations
(hip, knee)
monkey wrench of the
femoral neck
brachymetacarpy
epiphyseal dysplasia
at 13 years of age: flessum of hips and knees
valgus deformation of the lower limbs
patella instability
multiple surgeries
weight 35 kg (1 SD)
height 98 cm (< -6 SD)
toe deformations
mild intellectual disability
Family 3
(male)
Belgian 1st cousins weight 2,570 g, length
39 cm, HC 33 cm
(term); transient
respiratory problems
in the neonatal period
flat face
low nasal bridge
blue sclerae
cleft palate
short neck
narrow thorax
short limbs
coronal clefts in the
neonatal period,
thereafter mild platyspondyly
shortening of tubular bones
absent ossification of
distal femoral epiphyses
at birth
at 12 years, 9 months of age: weight 23.7 kg
(3.5 SD)
height 109.5 cm (6 SD)
span 111 cm
HC 50.8 cm (2 SD)
flat face, prominent eyes, low nasal bridge
pectus carinatum, narrow thorax
hyperlaxity of fingers and knees (genua valga)
broad feet, toe clinodactyly
intellectual disability
Family 4 Turkish 1st cousins length 44 cm (term) at 3.5 months:
height 48.5 cm
head control: 2 months
hip dislocation (right)
knee dislocation
simian creases
hypermobile fingers
flat face
blue sclerae
neonatal period: advanced carpal
ossification
right hip and bilateral knee
dislocation
at 8 months: advanced bone age
elbow dislocation
at 11 months of age: height 56 cm
at 5.5 years of age: height 84 cm (5.5 SD)
coarse and round face
full cheek, long philtrum, mild micrognathia
hypermobile fingers
moderate truncal obesity
pectus excavatum
sitting at 9 months
walking at 3 years
Family 5 Turkish 1st cousins length 43 cm (term) at 52 days:
height 46 cm
round and flat face
epicanthal folds
short extremities
and hands
bilateral simian crease
neonatal period: monkey wrench
advanced carpal ossification,
short metacarpals and phalanges
widened anterior ribs
at 9 years: patella and elbow
subluxation
short iliac wings
at 13 months of age: height 59 cm
at 9 years of age: height 99 cm
at 13 years of age: height 109 cm (9 SD)
HC 53 cm
coarse and round face, blue sclera,
proptotic eyes
short extremities
increased lumbar lordosis
hypermobile joints
pectus excavatum
pes planus
truncal obesity
mild intellectual disability
sitting at 8 months
walking at 24 months
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408 The American Journal of Human Genetics 94, 405–414, March 6repeat-containing microsatellite markers: D16S405, D16S499
located on both sides ofXYLT1, and two intragenicmicrosatellites,
D16S103 and D16S3017. FAM-labeled PCR products were run on
an ABI 3130 sequencer and analyzed with GeneMapper (Applied
Biosystems).
Sequencing Analysis of XYLT1
The exons and exon-intron boundaries of XYLT1 were ampli-
fied with specific primers (available upon request). Amplification
products were purified by ExoSapIT (Amersham) and directly
sequenced with the Big Dye Terminator Cycle Sequencing Ready
Reaction kit v.1.1 on an automatic sequencer (ABI3130xl; PE
Applied Biosystems). Sequence analyses were performed with
Seqscape software v.2.5 (Applied Biosystems).
RNA Extraction, Reverse Transcription, and Real-Time
Quantitative PCR
Skin primary fibroblasts were cultured in DMEM medium supple-
mented with 10% fetal calf serum and antibiotics at 37C in
a humidified atmosphere containing 5% CO2. For real-time PCR
analyses, fibroblasts were seeded onto 96-well plates after stan-
dardization via the cell counter CASY Model TT (Roche). After
reverse transcription of mRNA with M-MLV reverse transcriptase
kit (Invitrogen), PCR analyses were performed on the 7300 Real
Time PCR System (Roche). The cDNA level of XYLT1, XYLT2,
and B4GALT7 was normalized to GAPDH.
Data were generated from three independent experiments per-
formed in quadruplate and compared to control data with one-
way ANOVA followed by Tukey’s post hoc correction test with
GraphPad Prism 6.0 software (GraphPad).
Analysis of PG Biosynthesis and Profile after
Metabolic Radiolabeling in Cultured Fibroblasts
Fibroblasts were seeded onto 6-well plates and incubated the
following day in Fischer’s medium containing 10 mCi/ml Na2[
35
S]SO4 in the presence of 5 mM of methylumbelliferyl-b-D-xylopyr-
anoside (4-MUX) or vehicle (DMSO) as described previously.19 Af-
ter radiolabeling, each cell media or cellular fractions were applied
to G-50 columns (GE Healthcare, VWR) and quantified by scintil-
lation counting on Packard 1600TR Tri Carb Liquid Scintillation
Analyzer.
To establish the PG profile, the PG fractions were digested for
4 hr at 37C by either the Chondroitinase ABC (cABC) from Pro-
teus vulgaris (Sigma-Aldrich) or by a mixture containing both
the Heparinases II and III from Flavobacterium heparinum (Sigma-
Aldrich). All samples were resolved by SDS-PAGE with Criterion
Precast gels (4%–15% Bis-Tris, Bio-Rad) and visualized by autoradi-
ography. In order to compare PG distribution, the same amount of
radioactivity was loaded in each well.Results
Identification of a Homozygous XYLT1 Mutation by
Whole-Exome Sequencing in Two Siblings withDBQD
Type 2
For exome-sequencing analysis, we first focused our ana-
lyses on nonsynonymous variants, splice acceptor and
donor site mutations, and coding indels, anticipating
that synonymous variants were far less likely to cause
disease (Table 2). We also defined variants as previously, 2014
Table 2. Filtering Procedure for Bioinformatic Analysis
Individuals
Single-Nucleotide Variations
Total Without Duplicatesa Not in Databasesb
In Essential Splicing and
Coding Regionsc
Deleterious/Damaging
or Unknownd
Family 1, sibling 1 (Csg) 11,534 5,560 216 60 11
Family 1, sibling 2 (Csg) 11,324 5,245 159 35 4
Family 1, siblings 1þ2 8,881 4,590 70 18 2
Abbreviation is as follows: Csg, consanguinity.
aWithout duplicates resulting from the homozygous status of subjects.
bDatabases searched were dbSNP, 1000 Genomes, Exome Variant Server, and in-house exomes.
cVariants included were essential splicing and nonsynonymous (missense, nonsense, deletion and insertion); eliminated variants were intergenic or intronic non-
coding RNA or UTR splicing.
dAs determined by SIFT or PolyPhen.unidentified if they were absent from both control pop-
ulations and data sets including dbSNP129, the 1000
Genomes Project, and in-house exome data.
Based on the recessive mode of inheritance of DBQD,
two genes were found to harbor an identical homozygous
substitution in the two siblings: the structural mainte-
nance of chromosome 1B (SMC1B [MIM 608685], RefSeq
accession number NM_148674.3) and the xylosyltransfer-
ase 1 gene (XYLT1, RefSeq NM_022166.3) (Table 2). These
results were confirmed by direct sequencing.20 The
SMC1B (c.11T>G [p.Leu4Arg]) and XYLT1 (c.1792C>T
[p.Arg598Cys]) substitutions cosegregated with the dis-
ease, were present at the heterozygous state in the par-
ents, and were considered pathogenic in the PolyPhen
and Sift analytical programs. SMC1B belongs to the cohe-Figure 3. Schematic Representation of the PG Biosynthesis
XT-I and XT-II participate in the initiation of the PG biosynthesis
by transferring a Xyl to specific Ser residues of the core protein.
Two Gal and one GlcUA will be sequentially added via the action
of GalT-I, GalT-II, and GlcAT-I to form the common linker region.
The addition of a GalNAc will then initiate the assembly of chon-
droitin-sulfate/dermatan-sulfate (CS/DS) chains while addition of
a GlcNAc will initiate the synthesis toward heparan-sulfate/hepa-
rin (HS/Hep) chains. Mutations in genes involved in the assembly
of the common linker region have been associated with several
disorders, namely DBQD type 2 (XYLT1), Ehlers-Danlos progeroid
syndrome, type 1 (B4GALT7), Ehlers-Danlos progeroid syndrome,
type 2/spondyloepimetaphyseal dysplasia with joint laxity type 1
(SEMD-JL1) (B3GALT6), and Larsen-like syndrome (B3GAT3).
The Amesin family required for chromatid cohesion and DNA
recombination during meiosis and mitosis. Nevertheless,
because XT-I catalyzes the very first step of PG biosyn-
thesis (Figure 3) and owing to functional relevance of
PGs in extracellular matrix, we considered XYLT1 as our
best candidate gene and undertook its study in the 19 re-
maining families affected by DBQD type 2. XYLT1 is
composed of 12 exons encoding a protein of 959 amino
acids (aa) consisting of two domains, the glycosyltransfer-
ase family 14 domain (aa 328–581) and the xylosyltrans-
ferase domain (aa 613–794).
Among the 19 remaining families affected by DBQD
type 2, 5/13 inbred individuals were homozygous at the
XYLT1 locus and direct sequencing was finally performed
in 11 families (including 6 nonconsanguineous families).
A total of five distinct XYLT1 mutations in seven individ-
uals (six families) with DBQD type 2 were identified (Fig-
ures 1 and 2, Tables 1 and 3). Two resulted in a premature
stop codon (c.276dupG [p.Pro93Alafs*69], c.439C>T
[p.Arg147*]) located N-terminal to the glycosyltransferase
family 14 and xylosyltransferase domains; two were splice
site mutations (c.12902A>C, c.15883C>T) located in
the donor sites of exons 6 and 8, respectively, involved
in the glycosyltransferase family 14 domain; and one
was a missense substitution (c.1792C>T [p.Arg598Cys])
located in the xylosyltransferase domain, considered
as damaging in PolyPhen and Sift analytical programs
(Figure 4, Table 3). All mutations segregated with the dis-
ease and were not identified in 200 control chromosomes.
SMC1B was excluded by linkage analysis in the remaining
five consanguineous families with XYLT1 mutations.XYLT1 Mutations Are Correlated with a Decrease of
cDNA Level in Two Cultured Individual Fibroblasts
By quantifying the cDNA level of XYLT1 in the two
cultured individual fibroblasts (p.Arg147*, female aged
14; and p.Pro93Alafs*69, male aged 23), we found a dra-
matic reduction of XYLT1 cDNA level (Figure 5A). Because
the two xylosyltransferases XT-I and XT-II14 can both
initiate the synthesis of GAG chains to PG core proteins,
we also measured the cDNA level of XYLT2 and found
a significant decrease of XYLT2 expression in the tworican Journal of Human Genetics 94, 405–414, March 6, 2014 409
Table 3. XYLT1 Mutations in the Six DBQD Type 2-Affected Families
Family Ethnic Origin Csg No. of Affected Children Nucleotide Change Status Amino Acid Change Location
1 Tunisian yes 2 c.1792C>T Ho p.Arg598Cys Ex9
2 Mauritian yes 1 c.439C>T Ho p.Arg147* Ex3
3 Belgian yes 1 c.276dupG Ho p.Pro93Alafs*69 Ex1
4 Turkish yes 1 c.15883C>T Ho ? In7
5 Turkish yes 1 c.12902A>C Ho ? In5
6 Turkish yes 1 c.12902A>C Ho ? In5
Abbreviations are as follows: Csg, consanguinity; ho, homozygote; ?, mutation not localized in a protein domain.individual cell lines when compared to control 2 (male,
aged 12). No significant differences were found when indi-
vidual data were compared to control 1 (female, aged 2.5;
Figure S1 available online).
By contrast, the cDNA level of B4GALT7, which encodes
the glycosyltransferase (GT) that adds the second sugar
galactose (Gal) to the xylose (Xyl), was not affected by
XYLT1 mutations (Figures 3 and S1).The PG Biosynthesis Is Strongly Affected by XYLT1
Mutations in the Two Cultured Individual Fibroblasts
To evaluate the impact of the loss of function of XYLT1,
the cells were treated with the 4-MUX, an exogenous
acceptor substrate of the GalT-I that can increase GAG
synthesis (Figure 3). No major differences in the sulfate
incorporation level were found for the extracellular
fractions in the absence of 4-MUX. In the presence of
4-MUX, a significant increase of sulfate incorporation
was observed, indicating that GAG biosynthesis was initi-
ated and enhanced by the 4-MUX via the GalT-I activity
(Figure S2). In contrast, the incorporated sulfate level asso-
ciated with the cellular fractions was significantly lower in
the two cultured individual fibroblasts and no increase was
observed after the addition of 4-MUX (Figure 6).Modifications in PG Pattern Are a Consequence of
XYLT1 Mutations
An important reduction of secreted and large chondroitin-
sulfate proteoglycan (CSPG) production was observed inFigure 4. Location of the Five XYLT1 Mutations
Organization of XYLT1 gene and protein with the two glycosyltrans
410 The American Journal of Human Genetics 94, 405–414, March 6the two cultured individual fibroblasts (lanes 4, 6, 7, and
9, Figure 7). In the p.Arg147* cell line, the presence of a
stronger second band at 90 kDa (lanes 7 and 9, Figure 7)
was observed, presumably corresponding to the accumula-
tion in the extracellular media of other small CSPGs such
as decorin. For individual and control fibroblast cell lines,
the addition of 4-MUX led to the production of GAG
chains with an increased ratio of lower-molecular-weight
GAGs. The sensitivity to Chondroitinase ABC treatment
supported that these GAG chains were mainly chon-
droitin-sulfate (CS) (lanes 11, 14, and 17, Figure 7). In
the p.Arg147* cultured fibroblasts, the accumulation of
CSPGs at 90 kDa was still observed after the xyloside addi-
tion (lanes 16 and 18, Figure 7).
For the cellular fractions, mainly heparan-sulfate proteo-
glycans (HSPGs) with high molecular weight (>200 kDa)
were detected and no major differences in PG profiles
and distribution were observed between control 2 and in-
dividual fibroblasts in the absence or presence of 4-MUX
(data not shown).Discussion
We report here the identification of XYLT1 mutations in
seven individuals from six families with DBQD type 2.
All individuals presented severe pre- and postnatal short
stature below –6 SD, flat face with prominent eyes, short
extremities, dislocations with monkey wrench appear-
ance of the femora, short long bones with metaphysealferase family 14 and xylosyltransferase domains
, 2014
Figure 5. cDNA Level of XYLT1 in Controls and Two Cultured In-
dividual Fibroblasts
cDNA levels were normalized to GAPDH. Individuals p.Arg147*
and p.Pro93Alafs*69 are female aged 14 and male aged 23 years,
respectively. Control 1 (female) and 2 (male) are aged 2.5 and 12
years, respectively. Control (black boxes) and individual (gray
boxes) data are presented as box plots and are the mean of three
independent experiments performed in quadruplate. ##p < 0.01,
###p < 0.001 compared to control 1, ***p < 0.001 compared to
control 2 by one-way ANOVA with Tukey’s post hoc test.
Note that mutations in XYLT1 affect cDNA level of XYLT1.
Figure 6. Sulfate Incorporation of Cellular Fractions in Controls
and the Two Cultured Individual Fibroblasts in the Presence of
4-MUX or Vehicle
The black (þ4-MUX, 5 mM) and white (DMSO vehicle) bars repre-
sent the mean5 SEM of two independent experiments performed
in triplicate. ***p < 0.001 when compared to the control 2 by one-
way ANOVA with Tukey’s post hoc test.
Note thatXYLT1mutations have an impact on the biosynthesis of
cellular PGs in the two cultured individual fibroblasts.widening, epiphyseal dysplasia, and advanced carpal and
tarsal ossification. No significant clinical or radiological
differences could be found with the remaining 14 DBQD
type 2 subjects with unknown molecular bases. How-
ever, long-term follow-up of XYLT1-mutated individuals
emphasizes the severity of the short stature (<6 SD)
contrasting with obesity, lower limb and foot defor-
mities requiring often repeated surgeries, and intellectual
disability (5/7). Interestingly, respiratory distress was pre-
sent at birth in 4/7 subjects and spontaneously resolved
in the first years of life but thorax narrowness persisted
in the eldest children. No major scoliosis was observed.
Among the five mutations identified, four were expected
to result in loss of function, confirmed in two by the
demonstration of a drastic reduction of gene expression
in cultured fibroblasts. The substitution p.Arg598Cys iden-
tified is located in a highly conserved region of the protein,
between the glycosyltransferase family 14 and the catalytic
domains of the enzyme,21 pointing out possible changes
in the protein folding and/or stability as the positively
charged amino acid Arg is replaced by a polar and neutral
Cys residue. Very recently, another substitution of XT-I
(p.Arg481Trp) has been reported in Turkish siblings
presenting short stature and minor skeleton features asso-
ciated with intellectual disability.22 X-rays of the two sib-
lings (aged 16 and 18 years) do not show monkey wrench
appearance of the femoral neck or advanced carpal bone
age, but these features disappear in the course of DBQD.
However, among features listed in the two siblings,
coxa valga, broad thumbs, abnormal feet, and obesity areThe Amereminiscent of DBQD spectrum. The milder phenotype
observed in the two siblings might be due to a partial
loss of function of XT-I.22
PG formation begins with the synthesis of a common
linker chain of four sugar residues. The very first step
of this process can be catalyzed by the two paralogs XT-I
and XT-II14 leading to the initiation of the two types
of GAG chains (Figure 3).23 Our finding of decreased
XYLT2 cDNA level in two individual fibroblasts suggests
that XYLT1 loss of function may affect XYLT2 gene
expression. However, because of the variability observed
in cultured fibroblasts (even in control samples), this
observation will need to be confirmed in additional indi-
vidual samples compared to age- and gender-matched
control samples.
The two paralogs XT-I and XT-II exhibit a high degree
of homology within their catalytic domain24 and are ubiq-
uitously expressed in human tissues (data not shown).25,26
Despite the apparent redundancy in catalytic activity
as demonstrated by in vitro enzymatic assays25,26 and in
gene expression, the identification of XYLT1 mutations
in a severe chondrodysplasia supports a pivotal role of
XYLT1 during the ossification process. The specific impli-
cation of XT-I in skeletal development and during carti-
lage repair has been previously reported.27,28 Moreover, a
recent study describing the phenotype of the pug mouse
mutant carrying a homozygous missense mutation in
Xylt1 and characterized by a disproportionate dwarfism,
premature chondrocyte maturation, and increased Indian
Hedgehog signaling further supports a key role of XT-I in
early chondrocyte maturation and skeletal length.29rican Journal of Human Genetics 94, 405–414, March 6, 2014 411
Figure 7. Gel Electrophoresis of Radiolabeled GAG Chains Ex-
tracted from Control 2 and the Two Cultured Individual Fibro-
blasts Media in the Presence 4-MUX or Vehicle
For each sample, three lanes corresponding to nondigested (ND),
digested by the Chondroitinase ABC (Ch), and digested by the
Heparinases II and III (Hp) were loaded onto the gel and the vol-
umes were adjusted to dpmvalues to visualize GAGprofile and dis-
tribution. Control 2 (male) is aged 12.
Note that mutations in XYLT1 change the distribution and profile
of secreted PGs in the two cultured individual fibroblasts.The presence of intellectual disability was observed in
at least five subjects and highlights also a possible role of
XYLT1 in brain development. Interestingly, common
CSPGs such as aggrecan, perlecan, and biglycan are both
found in cartilage and expressed during brain develop-
ment.30,31 Our findings that mainly CSPGs were secreted
into the cell media and that synthesis of large CSPGs was
clearly reduced for the p.Arg147* cell line suggest that
both PG-specific expression pattern and impaired synthe-
sis of large CSPGs may contribute to the tissue specificity
of the disease. Interestingly, a strong decrease of sulfate
incorporation in the high-density PG fraction (mainly
CSPGs) was also observed in the pug mutant.29 Finally,
the accumulation of PGs in the range of 90 kDa observed
for the p.Arg147* cell line could compensate the important
loss of high-molecular-weight CSPGs, whereas for the
p.Pro93Alafs*69 cell line, the loss of large CSPGs was less
pronounced.
The consequences of XYLT1 mutations on PG synthesis
were also clearly illustrated by a significant reduction of
cellular PG synthesis in the two cultured individual fibro-
blasts. This reduction could not be rescued by the addition
of 4-MUX, indicating that most of the 4-MUX-primed
GAGs were presumably secreted into the cell media.
Because XT-I catalyzes the first step of PG synthesis, an
altered expression of this enzyme is likely to impact PG
synthesis either by limiting the initiation of the GAG
chains or (less probably) by leading to an abnormal
decrease of the PG core protein level.
Interestingly, trials based on the use of either heparin-
like molecules in animals32 to repair skull defects or HS412 The American Journal of Human Genetics 94, 405–414, March 6supplementation33 in cultures of human mesenchymal
stem cells have already been tested. Although protein
xylosylation is known to be the rate-limiting step in PG
biosynthesis, this can be bypassed by the addition of exog-
enous xylosides (such as 4-MUX) into cell media owing
to the GalT-I activity. Our findings of identical B4GALT7
cDNA level in controls and individual fibroblasts but
increased GAG production in response to 4-MUX treat-
ment in individual fibroblasts may support the develop-
ment of new approaches based on the use of GAGs.
To date, mutations in genes involved in the synthesis
of the common linker region have been identified in
b1,4-galactosyltransferase 7 (GalT-I ¼ B4GALT7 [MIM
604327]),34–36 b1,3-galactosyltransferase 6 (GalT-II ¼
B3GALT6 [MIM 615291]),37,38 and b1,3-glucuronosyltrans-
ferase I (GlcAT-I ¼ B3GAT3 [MIM 606374]),39 and the
human phenotypes associated included Ehlers-Danlos
progeroid type (type 1 MIM 130070, type 2 MIM
615349), spondylo-epiphyseal-meta-dysplasia with joint
laxity type 1 (SEMD-JL1 [MIM 271640]), and a Larsen-
like phenotype with heart defect (MIM 245600). Perturba-
tions in GAG modifications (mainly sulfation) have been
also reported in (1) spondyloepiphyseal dysplasia (SED)
with dislocations resulting from CHST3 mutations
(C6ST-1) responsible for altered sulfation of CSPGs,40 (2)
a chondrodysplasia with joint dislocations resulting from
mutations in IMPAD1 that encodes for the golgi-resident
nucleotide phosphatase gPAPP and resulting in an under-
sulfation of PGs,11 and (3) DBQD resulting from CANT1
mutations accounting for shorter GAG chains.7
Our findings of XYLT1 mutations in DBQD type 2
further confirm a common physiological basis in the group
of multiple dislocation disorders involving PG synthesis
and also shed light on the pivotal and specific role of
XT-I during the ossification process.Supplemental Data
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